Arovella receives additional R&D tax rebate of $0.28 million
MELBOURNE, AUSTRALIA 25 March 2026: Arovella Therapeutics Ltd (ASX: ALA) ACN 090 987 250 (Arovella or the Company) is pleased to announce that it has received an additional amount of $0.28 million as part of its FY2025 R&D Tax Incentive. This is in relation to eligible expenditure covered by an advanced overseas finding that was successfully obtained post lodgment of its original income tax return that resulted in the $3.2 million refund. These funds further strengthen Arovella’s cash position as it progresses its lead asset, ALA-101, towards first-in-human clinical trials.
CEO and Managing Director, Dr Michael Baker, commented “We are delighted to receive additional funds through the R&D Tax Incentive scheme. The scheme provides valuable support for companies such as Arovella and we look forward to using these funds to support the progression of ALA-101 into a first-in-human phase 1 clinical trial. .”
The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with cash refunds for 43.5-48.5% of eligible expenditure on research and development activities.